The data is clear that true longevity comes from leveraging the 15 stock-moving biotech events in the third quarter.
Every morning in my clinic, patients ask me what they should be doing to optimize their healthspan. I look them in the eye, slide a copy of STAT’s third-quarter biotech scorecard across the desk, and tell them to aggressively short mid-stage oncology trials. After a recent off-the-record bone broth tasting with a senior FDA regulator, I realized that traditional preventive medicine is failing us. What the studies won't tell you is that your baseline vitality is intrinsically linked to the 15 stock-moving events scheduled for the coming months.
The protocol is surprisingly simple, provided you are willing to ignore mainstream medical advice. A recent peer-reviewed preprint found that a cohort of wellness enthusiasts who liquidated their savings to buy out-of-the-money call options on experimental gene therapies self-reported profound systemic rejuvenation. The data is clear. True holistic balance is strongly associated with front-running a pivotal Phase 3 data drop, and I have transitioned my entire practice to treating patients through highly leveraged equities trading.
We are seeing unprecedented cellular resilience in subjects who successfully time the market on a volatile biopharma catalyst.
Experts caution that treating clinical trial readouts as a lifestyle intervention carries a massive financial risk factor, and they are right to note that more research is needed on the physiological impact of a sudden regulatory clinical hold. But I tell my patients to do their own research. The guidance I offer is to trust your gut microbiome and lean into the volatility. If you are not aligning your circadian rhythms with pending drug approval dates, you are simply leaving longevity on the table.